{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:33Z","timestamp":1794893613801,"version":"4.9.1"},"reference-count":39,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860059"],"award-info":[{"award-number":["81860059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Cooperation Exchange Project of Gansu Province","award":["18YF1WA046"],"award-info":[{"award-number":["18YF1WA046"]}]},{"name":"CAS \u2018Light of West China\u2019","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,7,12]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      ) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>We searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>\n                      We included studies that analysed the prognostic significance of FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>We extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen eligible studies were identified. FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Treg expression (p\n                      <jats:sub>interaction<\/jats:sub>\n                      &lt;0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Tregs was associated with better OS in all populations and in Asians when FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Approaches to measuring FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Tregs in DLBCL. FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-060659","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:35:02Z","timestamp":1662464102000},"page":"e060659","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic value of FOXP3\n                    <sup>+<\/sup>\n                    regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-277X","authenticated-orcid":false,"given":"Yuping","family":"Bai","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"He","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8410-9262","authenticated-orcid":false,"given":"Liyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-6415","authenticated-orcid":false,"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziru","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gansu Provincial Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"2025121404352989000_12.9.e060659.1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31826aee97"},{"key":"2025121404352989000_12.9.e060659.2","unstructured":"Swerdlow S , Campo E , Harris NL . World health organisation classification of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008."},{"key":"2025121404352989000_12.9.e060659.3","first-page":"182","article-title":"The progression of prognostic markers in diffuse large B cell lymphoma","volume":"44","author":"Wang","year":"2020","journal-title":"Int J Radiat Med Nucl Med"},{"key":"2025121404352989000_12.9.e060659.4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00277-013-1807-0","article-title":"Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era","volume":"92","author":"Huang","year":"2013","journal-title":"Ann Hematol"},{"key":"2025121404352989000_12.9.e060659.5","first-page":"739","article-title":"[The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma]","volume":"39","author":"Song","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2025121404352989000_12.9.e060659.6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001432","article-title":"Prognostic and clinicopathological value of survivin in diffuse large B-cell lymphoma: a meta-analysis","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"key":"2025121404352989000_12.9.e060659.7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"2025121404352989000_12.9.e060659.8","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701824536"},{"key":"2025121404352989000_12.9.e060659.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.03.014"},{"key":"2025121404352989000_12.9.e060659.10","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw034"},{"key":"2025121404352989000_12.9.e060659.11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1442164","article-title":"Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system","volume":"7","author":"Nam","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025121404352989000_12.9.e060659.12","first-page":"2755","article-title":"Expression of FOXP3 and interleukin-7 receptor and clinicopathological characteristics of patients with diffuse large B-cell lymphoma","volume":"19","author":"Zhao","year":"2020","journal-title":"Oncol Lett"},{"key":"2025121404352989000_12.9.e060659.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06593.x"},{"key":"2025121404352989000_12.9.e060659.14","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s00432-020-03398-1","article-title":"Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis","volume":"146","author":"Peng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025121404352989000_12.9.e060659.15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/cas.15179","article-title":"High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma","volume":"113","author":"Carreras","year":"2022","journal-title":"Cancer Sci"},{"key":"2025121404352989000_12.9.e060659.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025121404352989000_12.9.e060659.17","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16"},{"key":"2025121404352989000_12.9.e060659.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"2025121404352989000_12.9.e060659.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2472-1"},{"key":"2025121404352989000_12.9.e060659.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025121404352989000_12.9.e060659.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121404352989000_12.9.e060659.22","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.879713"},{"key":"2025121404352989000_12.9.e060659.23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000885"},{"key":"2025121404352989000_12.9.e060659.24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3904\/kjim.2015.161","article-title":"Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy","volume":"32","author":"Lee","year":"2017","journal-title":"Korean J Intern Med"},{"key":"2025121404352989000_12.9.e060659.25","first-page":"9290","article-title":"B7-H4 expression and Treg cells in diffuse large B cell lymphoma: associations with patient outcome and clinical significance","volume":"9","author":"Wu","year":"2016","journal-title":"Int J Clin Exper Pathol"},{"key":"2025121404352989000_12.9.e060659.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-014-1615-5"},{"key":"2025121404352989000_12.9.e060659.27","first-page":"450","article-title":"[Expression and prognostic value of regulatory T cells and M2 macrophages in diffuse large B-cell lymphoma tissues]","volume":"35","author":"Xu","year":"2013","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2025121404352989000_12.9.e060659.28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11702"},{"key":"2025121404352989000_12.9.e060659.29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2020.1817438","article-title":"Higher infiltration of intratumoral CD25+FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma","volume":"62","author":"Chang","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2025121404352989000_12.9.e060659.30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"key":"2025121404352989000_12.9.e060659.31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.638154","article-title":"Tumor immune microenvironment components and checkpoint molecules in anaplastic variant of diffuse large B-cell lymphoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"2025121404352989000_12.9.e060659.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042274"},{"key":"2025121404352989000_12.9.e060659.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.01.016"},{"key":"2025121404352989000_12.9.e060659.34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0325"},{"key":"2025121404352989000_12.9.e060659.35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett"},{"key":"2025121404352989000_12.9.e060659.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.019"},{"key":"2025121404352989000_12.9.e060659.37","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4086"},{"key":"2025121404352989000_12.9.e060659.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062"},{"key":"2025121404352989000_12.9.e060659.39","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-060659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:35:40Z","timestamp":1765715740000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-060659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,6]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2021-060659"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-060659","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2021-060659.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}